Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes

Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes

Abstract Teplizumab is approved for delaying the diagnosis of type 1 diabetes by modulating progression of disease. Compared to EBV-seronegative patients, those who are EBV-seropositive prior to treatment have a more robust response to teplizumab in two clinical trials. Here we compare the phenotype...

Full description

Saved in:
Bibliographic Details
Main Authors: Ana Lledó-Delgado, Paula Preston-Hurlburt, Lauren Higdon, Alex Hu, Eddie James, Noha Lim, S. Alice Long, James McNamara, Hai Nguyen, Elisavet Serti, Tomokazu S. Sumida, Kevan C. Herold
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-60276-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-60276-5

Similar Items